报价延迟最少15分钟:2026/03/02 20:00 EST
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
15.795 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-3.05/-3.11
|
|
企业价值
1.70B
|
| 资产负债 |
|
每股账面净值
5.24
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
83.98M
|
|
每股收益
0.67
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| Nurix Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and potential commercialization of targeted protein degradation therapies for cancer and inflammatory diseases. It utilizes an integrated discovery platform that incorporates artificial intelligence and ligase expertise to support its research activities. The company's pipeline includes Bexobrutideg (NX-5948), Zelebrudomide (NX-2127), NX-1607 and BRAF degrader. These drug candidates target specific proteins involved in immune and cancer-related pathways. It operates in a single business segment. |
